In a murine mesothelioma model, locally delivered imiquimod in combination with systemic anti-CD40 immunotherapy not only significantly enhanced the local antitumor response with 30% complete resolution, but also inhibited distal tumor growth [17]. Here, CD40 is linked to neoplasm.